CA
NZ
UK
AU
IND
US
…
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies aimed at treating Alzheimer’s disease and related neurodegenerative disorders by targeting synaptic dysfunction caused by toxic protein oligomers. Its long-term growth may be supported by advancement of clinical-stage programs, an aging population with large unmet medical need, and potential partnerships or label expansions, and the company appears positioned to attract investors focused on novel Alzheimer's approaches.
Key investment risks include high clinical and regulatory uncertainty, reliance on a limited pipeline and external financing, and strong competition from other Alzheimer’s therapeutic programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -23.49M | -33.97M | -25.79M | -21.40M | -11.72M |
| Net income | -23.49M | -33.97M | -25.79M | 0.76M | -10.29M |
| Selling general administrative | 10.61M | 12.29M | 13.53M | 13.23M | 10.03M |
| Selling and marketing expenses | - | - | 0.25M | - | - |
| Gross profit | -0.23M | -0.27M | -0.25M | - | - |
| Reconciled depreciation | 0.23M | 0.27M | 0.25M | 0.23M | 0.09M |
| Ebit | -48.03M | -33.95M | -25.76M | -43.55M | -28.60M |
| Ebitda | -47.80M | -33.68M | -25.51M | -21.13M | -13.38M |
| Depreciation and amortization | 0.23M | 0.27M | 0.25M | 22.42M | 15.22M |
| Non operating income net other | - | - | - | -0.04M | - |
| Operating income | -47.80M | -53.97M | -50.72M | -43.55M | -28.60M |
| Other operating expenses | 47.80M | 53.97M | 50.72M | 21.33M | 11.15M |
| Interest expense | 0.01M | 0.03M | 0.03M | 0.03M | 0.89M |
| Net interest income | -0.01M | -0.03M | -0.03M | -0.03M | -0.89M |
| Income tax expense | - | - | - | -22.15M | -1.43M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 47.80M | 53.97M | 50.72M | 21.33M | 11.15M |
| Cost of revenue | 0.23M | 0.27M | 0.25M | - | - |
| Total other income expense net | 24.31M | 20.00M | 24.94M | 22.15M | 16.88M |
| Net income from continuing ops | -23.49M | -33.97M | -22.83M | -43.61M | -11.72M |
| Net income applicable to common shares | - | - | - | -21.40M | -16.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 48.39M | 30.23M | 35.16M | 50.42M | 59.14M |
| Other current assets | 1.26M | 1.86M | 3.02M | 2.41M | 0.01M |
| Total liab | 14.12M | 11.48M | 10.69M | 10.18M | 7.86M |
| Total stockholder equity | 34.27M | 18.75M | 24.47M | 40.25M | 51.27M |
| Other current liab | 11.99M | 7.62M | 4.60M | 2.09M | 3.70M |
| Common stock | 0.09M | 0.06M | 0.03M | 0.03M | 0.02M |
| Capital stock | 0.09M | 0.06M | 0.03M | 0.03M | 0.02M |
| Retained earnings | -198.65M | -175.16M | -141.19M | -115.40M | -94.00M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 36.81M | 25.01M | 29.92M | 41.56M | 54.72M |
| Total current liabilities | 13.92M | 11.14M | 10.17M | 7.79M | 7.86M |
| Current deferred revenue | 0.37M | 1.07M | 1.70M | 1.70M | - |
| Net debt | -36.17M | -24.20M | -29.75M | -40.08M | -54.72M |
| Short term debt | 0.44M | 0.47M | 0.17M | 0.78M | - |
| Short long term debt | 0.31M | 0.28M | 0.54M | 0.63M | - |
| Short long term debt total | 0.64M | 0.81M | 0.17M | 1.48M | - |
| Other stockholder equity | 232.83M | 193.85M | 165.83M | 155.82M | 86.32M |
| Property plant equipment | - | - | - | 0.23M | 0.14M |
| Total current assets | 47.99M | 29.55M | 34.22M | 47.65M | 58.99M |
| Net tangible assets | - | - | - | 40.25M | 51.27M |
| Net receivables | 9.92M | 2.69M | 1.28M | 3.67M | 2.27M |
| Inventory | - | - | - | - | 1.99M |
| Accounts payable | 1.12M | 1.98M | 3.69M | 3.22M | 4.17M |
| Accumulated other comprehensive income | - | - | -0.20M | -0.20M | -0.20M |
| Common stock total equity | - | - | - | 0.03M | - |
| Retained earnings total equity | - | - | - | -115.40M | - |
| Non currrent assets other | - | - | -0.00M | 1.73M | - |
| Non current assets total | 0.40M | 0.68M | 0.94M | 2.78M | 0.14M |
| Capital lease obligations | 0.33M | 0.54M | 0.69M | 0.84M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.00M | -0.13M | -0.17M | -0.03M |
| Change to liabilities | - | - | - | -0.75M | 2.17M |
| Total cashflows from investing activities | 0.01M | -0.00M | -0.15M | -0.17M | -0.03M |
| Net borrowings | -0.35M | -0.74M | -0.81M | -1.40M | -0.27M |
| Total cash from financing activities | 36.57M | 23.57M | 4.52M | 5.55M | 53.20M |
| Change to operating activities | - | - | - | - | 0.56M |
| Net income | -23.49M | -33.97M | -25.79M | -21.40M | -11.72M |
| Change in cash | 11.99M | -4.91M | -11.64M | -13.16M | 49.53M |
| Begin period cash flow | 25.01M | 29.92M | 41.56M | 54.72M | 5.19M |
| End period cash flow | 37.00M | 25.01M | 29.92M | 41.56M | 54.72M |
| Total cash from operating activities | -24.59M | -28.47M | -16.02M | -18.53M | -3.63M |
| Issuance of capital stock | 37.02M | 24.35M | 8.04M | 5.32M | 44.22M |
| Depreciation | 0.23M | 0.27M | 0.25M | 0.23M | 0.09M |
| Other cashflows from investing activities | 0.01M | -0.00M | - | - | - |
| Change to inventory | - | - | -2.44M | - | - |
| Change to account receivables | -7.24M | -1.41M | 2.39M | - | 0.12M |
| Sale purchase of stock | - | - | - | 6.94M | - |
| Other cashflows from financing activities | -0.16M | -0.05M | -0.15M | 1.62M | 9.25M |
| Change to netincome | - | - | - | 3.57M | 4.77M |
| Capital expenditures | 0.00M | 0.00M | 0.15M | 0.17M | 0.03M |
| Change receivables | - | - | - | 0.47M | - |
| Cash flows other operating | - | - | - | -0.51M | - |
| Cash and cash equivalents changes | - | - | - | -13.16M | - |
| Change in working capital | -3.46M | 1.29M | 4.85M | -0.94M | 2.84M |
| Stock based compensation | 2.09M | 3.75M | 4.35M | 3.57M | 5.18M |
| Other non cash items | 0.04M | 0.20M | 0.32M | - | 0.38M |
| Free cash flow | -24.59M | -28.48M | -16.16M | -18.70M | -3.66M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| CGTX Cognition Therapeutics Inc |
-0.01 1.42% |
0.70 | - | - | - | 2.92 | -0.44 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
| Name | Title | Year Born |
|---|---|---|
| Ms. Lisa Ricciardi | CEO, Pres & Director | 1960 |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D | NA |
| Mr. Andrew J. Einhorn CPA | Interim Chief Financial Officer | 1960 |
| Ms. Lisa Ricciardi | CEO, President & Director | 1960 |
| Mr. John Brendan Doyle | Chief Financial Officer | 1977 |
| Dr. Steven A. Weissman Ph.D. | VP & Head of CMC | NA |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D | 1970 |
| Ms. Anita Cornet | Head of Quality | NA |
| Mr. Bobby Horn | Corporate Controller | NA |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...